Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jackson Laboratory Resource Report Resource Website 10000+ mentions |
Jackson Laboratory (RRID:SCR_004633) | JAX | institution | An independent, nonprofit organization focused on mammalian genetics research to advance human health. Their mission is to discover the genetic basis for preventing, treating, and curing human disease, and to enable research for the global biomedical community. Jackson Laboratory breeds and manages colonies of mice as resources for other research institutions and laboratories, along with providing software and techniques. Jackson Lab also conducts genetic research and provides educational material for various educational levels. | genomic, disease, mouse model, human disease, biomaterial manufacture |
is listed by: One Mind Biospecimen Bank Listing is affiliated with: Integrative Human Microbiome Project is related to: ScienceExchange is related to: Federation of International Mouse Resources is related to: MGI strains is related to: One Mind Biospecimen Bank Listing is related to: Beta Cell Biology Consortium is related to: Mouse Mutagenesis Center for Developmental Defects is related to: GenomeMUSter is parent organization of: Mouse Models For Alzheimer's Disease Research is parent organization of: Type 1 Diabetes Resource is parent organization of: MouseCyc is parent organization of: Special Mouse Strains Resource is parent organization of: Gene Weaver is parent organization of: Mouse Phenome Database (MPD) is parent organization of: Jackson Laboratory Cytogenetic Models Resource is parent organization of: Parkinson's Disease Mouse Model Resource is parent organization of: Eye mutant resource - The Jackson Laboratory is parent organization of: Brainbow mouse resource at Jackson Labs is parent organization of: Short Course on the Genetics of Addiction is parent organization of: JAX Cre Repository is parent organization of: Donate a strain to The Jackson Laboratory Repository is parent organization of: Jackson Laboratory Neurobiology is parent organization of: QTL Archive is parent organization of: Mouse Genome Informatics: The Gene Ontology Project is parent organization of: Mouse Genome Informatics (MGI) is parent organization of: Mouse Tumor Biology Database is parent organization of: Gene Expression Database is parent organization of: The Jackson Laboratory Hearing Research Program is parent organization of: JAX Mice: Neural Tube Defects is parent organization of: JAX Neuroscience Mutagenesis Facility is parent organization of: Induced Mutant Resource is parent organization of: Mouse Mutant Resource is parent organization of: Mouse Genome Database is parent organization of: Mutant Mouse Resource and Research Center is parent organization of: eMouseAtlas is parent organization of: GBRS is parent organization of: Jackson Laboratory Scientific Instrument Services Core Facility provides: Knockout Mouse Project Repository |
Types 1 diabetes, Type 2 diabetes, Diabetes, Cardiovascular diseases, Metabolic disease, Cancer, Rare disease, Alzheimer's disease, Demantia | Available to the research community, Available to the educational community | nlx_63162, ISNI: 0000 0004 0374 0039, grid.249880.f, Crossref funder ID: 100005946 | https://ror.org/021sy4w91 | SCR_004633 | JAX Lab, Jackson Lab | 2026-02-14 02:01:00 | 14831 | |||||
|
deStruct Resource Report Resource Website 1+ mentions |
deStruct (RRID:SCR_004747) | deStruct | software resource | A software tool for identifying structural variation in tumour genomes from whole genome illumina sequencing. | structural variation, genome, genomics |
is listed by: OMICtools has parent organization: Google Code |
Tumor, Cancer | Open unspecified license | OMICS_00314 | SCR_004747 | deStruct - Bioinformatics tool for identifying structural variation in tumour genomes | 2026-02-14 02:00:59 | 7 | ||||||
|
ABSOLUTE Resource Report Resource Website 100+ mentions |
ABSOLUTE (RRID:SCR_005198) | ABSOLUTE | software resource | Software to estimate purity / ploidy, and from that compute absolute copy-number and mutation multiplicities. When DNA is extracted from an admixed population of cancer and normal cells, the information on absolute copy number per cancer cell is lost in the mixing. The purpose of ABSOLUTE is to re-extract these data from the mixed DNA population. This process begins by generation of segmented copy number data, which is input to the ABSOLUTE algorithm together with pre-computed models of recurrent cancer karyotypes and, optionally, allelic fraction values for somatic point mutations. The output of ABSOLUTE then provides re-extracted information on the absolute cellular copy number of local DNA segments and, for point mutations, the number of mutated alleles. |
is listed by: OMICtools has parent organization: Broad Institute |
Cancer, Normal | PMID:22544022 | Account required | OMICS_00217 | SCR_005198 | 2026-02-14 02:01:03 | 263 | |||||||
|
qSNP Resource Report Resource Website 10+ mentions |
qSNP (RRID:SCR_005105) | qSNP | software resource | A single nucleotide variant caller optimised for identifying somatic variants in low cellularity cancer samples. |
is listed by: OMICtools has parent organization: University of Queensland; Brisbane; Australia |
Cancer | PMID:24250782 | OMICS_00089 | SCR_005105 | 2026-02-14 02:00:51 | 24 | ||||||||
|
Terry Fox Research Institute Resource Report Resource Website |
Terry Fox Research Institute (RRID:SCR_011568) | TFRI | institution | Launched in October 2007, TFRI is the brainchild of the Terry Fox Foundation. TFRI involves collaboration between cancer hospitals and research organizations across Canada, and will occur initially in British Columbia, Alberta, Ontario and Quebec. TFRI will support translational cancer research projects with the potential to significantly improve the health of cancer patients. TFRI is organized into functionally integrated yet geographically dispersed nodes. Regional cancer hospitals and research organizations participate in each node by providing space for researchers and by arranging for the participation of cancer patients in research projects. At each node, two node co-ordinators provide leadership, and bring together local scientific and clinical research teams to propose and manage specific projects. The TFRI headquarters team liaises with the TFRI nodes and provides direction, co-ordination and facilitates communication across the entire organization. The Terry Fox Foundation has committed a minimum of $50 million (CAN) over five years from donations obtained during the 25th anniversary of the Terry Fox Marathon of Hope and from new funds anticipated and those raised since 2005. Other partners sharing the same vision are being sought who will be asked to commit additional resources to support the ongoing work of the TFRI. | has parent organization: Terry Fox Foundation | Cancer | grid.489333.6, nlx_149428 | https://ror.org/00mtf6c40 | SCR_011568 | 2026-02-14 02:02:02 | 0 | ||||||||
|
DrGaP Resource Report Resource Website 10+ mentions |
DrGaP (RRID:SCR_008670) | DrGaP | software resource | Designed to identify Driver Genes and Pathways in cancer genome sequencing studies. | is listed by: OMICtools | Cancer | OMICS_00149 | SCR_008670 | 2026-02-14 02:01:43 | 10 | |||||||||
|
KGGSeq Resource Report Resource Website 50+ mentions |
KGGSeq (RRID:SCR_005311) | KGGSeq | software resource | A biological Knowledge-based mining platform for Genomic and Genetic studies using Sequence data. The software platform, constituted of bioinformatics and statistical genetics functions, makes use of valuable biologic resources and knowledge for sequencing-based genetic mapping of variants / genes responsible for human diseases / traits. It facilitates geneticists to fish for the genetic determinants of human diseases / traits in the big sea of DNA sequences. KGGSeq has paid attention to downstream analysis of genetic mapping. The framework was implemented to filter and prioritize genetic variants from whole exome sequencing data. | genomic, genetic, sequence, mutation, exome sequencing, disease, gene, variant, bio.tools |
is listed by: OMICtools is listed by: bio.tools is listed by: Debian |
Monogenic disorder, Cancer | PMID:22241780 | biotools:kggseq, OMICS_02260 | https://bio.tools/kggseq | SCR_005311 | KGGSeq: A biological Knowledge-based mining platform for Genomic and Genetic studies using Sequence data | 2026-02-14 02:00:52 | 53 | |||||
|
Finnish Cancer Registry Resource Report Resource Website 1+ mentions |
Finnish Cancer Registry (RRID:SCR_005881) | Finnish Cancer Registry | institution | The Finnish Cancer Registry maintains a nation-wide database on all cancer cases in Finland going back to 1953. It is also an internationally active institute for statistical and epidemiological cancer research. The Mass Screening Registry is a department of the Finnish Cancer Registry, and is responsible of planning and evaluating national cancer screening programs in Finland. The site contains information on cancer research and up to date statistics on the prevalence of different types of cancer in Finland, the Nordic countries and on a global level. The web pages include information for participants in cancer screening and for professionals involved in organizing such screening. | Cancer | Cancer Society of Finland | grid.424339.b, nlx_149446, ISNI: 0000 0000 8634 0612 | https://ror.org/00j15sg62 | SCR_005881 | 2026-02-14 02:01:01 | 8 | ||||||||
|
SPLINTER Resource Report Resource Website 10+ mentions |
SPLINTER (RRID:SCR_005826) | SPLINTER | software resource | Software that detects and quantifies short IN/DELs as well as single nucleotide substitutions in pooled-DNA samples. |
is listed by: OMICtools has parent organization: Washington University in St. Louis; Missouri; USA |
Cancer | Free for academic / non-profit use, Commercial use requires license | OMICS_00100 | SCR_005826 | Short IN/DEL Prediction by Large deviation Inference and Non-linear True frequency Estimation by Recursion | 2026-02-14 02:01:01 | 13 | |||||||
|
American Cancer Society Resource Report Resource Website 100+ mentions |
American Cancer Society (RRID:SCR_005756) | ACS | non profit organization | The American Cancer Society is the nationwide, community-based, voluntary health organization dedicated to eliminating cancer as a major health problem by preventing cancer, saving lives, and diminishing suffering from cancer, through research, education, advocacy, and service. Together with our millions of supporters, the American Cancer Society (ACS) saves lives and creates a world with less cancer and more birthdays by helping people stay well, helping people get well, by finding cures, and by fighting back. Headquartered in Atlanta, Georgia, the ACS has 12 chartered Divisions, more than 900 local offices nationwide, and a presence in more than 5,100 communities. | cancer, breast cancer, colon, lung, prostate, skin, breast | Cancer | grid.422418.9, Wikidata: Q463665, nlx_149219, ISNI: 0000 0004 0371 6485, Crossref funder ID: 100000048 | https://ror.org/02e463172 | SCR_005756 | American Cancer Society - The Official Sponsor of Birthdays | 2026-02-14 02:01:09 | 476 | |||||||
|
Ben and Catherine Ivy Foundation Resource Report Resource Website 1+ mentions |
Ben and Catherine Ivy Foundation (RRID:SCR_006333) | Ivy Foundation | funding resource | Funds patient-focused research on gliomas to develop better diagnostics and treatments that lead to long-term survival and a high quality of life for patients with brain tumors. The goal is to decrease the suffering of patients with brain tumors. With an ultimate goal to cure brain cancer, their immediate goal is to improve diagnostics and treatment. They are dedicated to improving the lives of all patients with brain cancer by funding research that they hope will lead to the doubling of life expectancy of patients with brain cancer. Their goal is to do this within the next seven years. Since 2005 they''ve committed more than $50 million to research into brain tumors, with the expectation that this will lead to better diagnostics and therapies. They are dedicated to this search because funding leads to answers, and answers lead to hope. | glioma, research, brain, tumor, brain tumor, diagnostic, treatment | Brain cancer, Cancer | nlx_152043 | SCR_006333 | 2026-02-14 02:01:16 | 2 | |||||||||
|
BC Cancer Foundation Resource Report Resource Website 1+ mentions |
BC Cancer Foundation (RRID:SCR_006428) | BC Cancer Foundation | institution | The fundraising partner of the BC Cancer Agency and the largest charitable funder of cancer research in this province. We enable donors to make contributions to leading-edge research that has a direct impact on improvements to cancer care for patients in British Columbia. By connecting philanthropy and research, we support the revolutionary advances that will help us achieve our vision of a world free from cancer. Our Cause: Supporting world-renowned cancer research in BC One in three British Columbians will be diagnosed with cancer in their lifetime. Because the BC Cancer Agency integrates research and treatment, the process from discovery to treatment is shorter, and researchers are asking questions focused on the needs of patients in BC. The BC Cancer Agency excels at translating exciting discoveries from the researcher''''s bench to the patient''''s bedside. This is the quickest and most effective way to impact cancer care, and it makes the Agency an international leader in cancer research. Our Donors: Leading the way in helping us advance our cause Our unique relationship with the BC Cancer Agency allows our donors to be part of research discoveries made right here in BC. We invite donors to become more connected to the BC Cancer Agency''''s world-leading research that is shaping the future of patient care. At the BC Cancer Foundation we are funding the areas of greatest priority and promise. We know, because we ask the scientists and clinicians at the BC Cancer Agency to identify the priorities and needs that will have the most significant and timely impact on cancer care and treatment. We then partner with our donors to raise the necessary funds in support of this life-saving work. Together we are funding and finding solutions that are having a direct impact on improving care for cancer patients in British Columbia. | british columbia, research | is related to: BC Cancer Agency | Cancer | nlx_151770, ISNI 0000 0001 0745 6244, grid.484001.9 | https://ror.org/03gqhbs95 | SCR_006428 | 2026-02-14 02:01:09 | 2 | |||||||
|
Celgene Resource Report Resource Website 50+ mentions |
Celgene (RRID:SCR_002955) | CELG | commercial organization | An American global biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. The company's major products are Thalomid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both Thalomid and Revlimid are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS. Celgene also receives royalties from Novartis Pharma AG on sales of the entire Ritalin family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD). (Adapted from Wikipedia) There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer. | biopharmaceutical, drug, immune, inflammatory, clinical, medical, hematological, tumor, myeloma, myelodysplatic, syndrome, lymphocyte, leukemia, lymphoma, glioblastoma, ovarian, pancreatic, prostate, medicine, biotechnology | uses: FluoroFinder | Cancer, Immune disease, Inflammatory disease, Attention-Deficit Hyperactivity Disorder | THIS RESOURCE IS NO LONGER IN SERVICE | nif-0000-30309 | SCR_002955 | Celgene Corporation | 2026-02-14 02:00:28 | 52 | ||||||
|
Dana-Farber Cancer Institute Resource Report Resource Website 1+ mentions |
Dana-Farber Cancer Institute (RRID:SCR_003040) | DFCI | institution |
Cancer institute that provides expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations, and disseminates innovative patient therapies and scientific discoveries to their target community across the United States and throughout the world. |
child, adult human, pediatric, young human |
has parent organization: Harvard Medical School; Massachusetts; USA is parent organization of: Spotfinder is parent organization of: TM4 Microarray Software Suite - TIGR MultiExperiment Viewer is parent organization of: Gene Index Project is parent organization of: CistromeMap is parent organization of: BINOCh is parent organization of: Dana Farber Tissue Bank is parent organization of: CistromeFinder is parent organization of: TM4 is parent organization of: WorfDB is parent organization of: Predictive Networks is parent organization of: RamiGO is parent organization of: DFCI Animal Resources Facility is parent organization of: DFCI Biohazard Containment Core Facility is parent organization of: DFCI Biospecimen Repository Core Facility is parent organization of: DFCI Blais Proteomics Center is parent organization of: DFCI Clinical Research Laboratory is parent organization of: DFCI Survey and Data Management Core is parent organization of: DFCI Flow Cytometry Core Facility is parent organization of: DFCI Medical Arts Core Facility is parent organization of: DFCI Microarray Core Facility is parent organization of: Dana-Farber Cancer Institute Molecular Biology Core Facility is parent organization of: DFCI RNA Interference Screening Facility is parent organization of: DFCI Shannon McCormack Advanced Molecular Diagnostics Laboratory is parent organization of: MAnorm is parent organization of: NPS is parent organization of: DFCI Confocal and Light Microscopy Core Facility is parent organization of: DFCI Monoclonal Antibody Core Facility is parent organization of: Dana-Farber Cancer Institute Labs and Facilities is parent organization of: DFCI Center for Cancer Computational Biology is parent organization of: GeneSigDB is parent organization of: MACS is parent organization of: DGAP |
Cancer | NCI ; Jimmy Fund |
Free, Freely available | Crossref funder ID: 100007886, grid.65499.37, Wikidata: Q1159198, ISNI: 0000 0001 2106 9910, nif-0000-30432 | https://ror.org/02jzgtq86 | SCR_003040 | Dana Farber Cancer Institute, Dana-Farber | 2026-02-14 02:00:37 | 6 | ||||
|
Janssen Research and Development Resource Report Resource Website 1+ mentions |
Janssen Research and Development (RRID:SCR_003904) | Janssen R&D | commercial organization | Pharmaceutical company with a mission to discover and develop innovative medicines that ease patients'' suffering, and solve the most important unmet medical needs of our time. As one of the Janssen Pharmaceutical Companies, their strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. They leverage their world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas: cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, and oncology. | pharmaceutical, oncology, immunology, neuroscience, vaccine, medical |
is related to: Investigator Databank is related to: eTRIKS is related to: Predict-TB is related to: OncoTrack is related to: European Lead Factory is related to: EU-AIMS is related to: GetReal is related to: Kinetics for Drug Discovery is related to: MIP-DILI is related to: NEWMEDS is related to: ORBITO is related to: PharmaCog is related to: PREDECT is related to: Structural Genomics Consortium is related to: Open PHACTS is related to: EMIF is parent organization of: Investigator Databank |
Infectious disease, Cardiovascular disease, Metabolic disease, Immunological disorder, Cancer | nlx_158241 | SCR_003904 | Janssen Research & Development LLC, Janssen Research & Development | 2026-02-14 02:00:33 | 2 | |||||||
|
Althia Resource Report Resource Website |
Althia (RRID:SCR_003918) | Althia | commercial organization | A biomedical company in Spain focused on the development of new tools for diagnosis and personalized treatment of oncological diseases and precancerous. It has three areas of activity in permanent innovation: Assistance in Diagnosis / Prognosis in solid and hematological tumors, Translational Research covering the gap between basic and clinical research and advanced radiotherapy treatments based image-guided single dose (SD-IGRT). Their objectives are: * Provide an integrated tissue and tumor molecular phenotype analysis using the most advanced technologies in diagnosis, to guide the most appropriate treatment for each patient. * Discover and validate molecular patterns by molecular systems and platforms including pathology, to generate predictive algorithms through computational biology, evolution and determining the response of patients with a particular tumor profile. Althia has laboratories equipped with the most advanced equipment and technologies in Barcelona and Granada Genyo Center, with offices in Madrid. | oncology, diagnosis, prognosis, solid tumor, hematological tumor, translational, radiation, phenotype, analysis, pathology, hematology, hereditary | is related to: PRECISESADS | Cancer, Tumor, Solid tumor, Hematological tumor, Precancer | nlx_158279 | SCR_003918 | Althia Health Ltd., Althia Health, Advanced Laboratories of Translational Health, SL, S.L. | 2026-02-14 02:00:38 | 0 | |||||||
|
Experimental Pharmacology and Oncology Berlin-Buch Resource Report Resource Website 1+ mentions |
Experimental Pharmacology and Oncology Berlin-Buch (RRID:SCR_003954) | EPO | commercial organization | A small and medium-sized enterprise (SME) that has expertise in preclinical pharmacology, pharmacokinetics, and toxicology for the characterization of novel anticancer therapeutics and predictive biomarkers like: cytostatics, biologicals (peptides, antibodies), (anti)-hormones, immunomodulators (cytokines), and gene therapeutics. EPO has modern laboratories licensed for animal experiments and gene technology (S2) and a broad panel of murine and human tumor models growing in immunocompetent (SPF-quality, syngeneic strains) or immunodeficient mice (nude, SCID, NOD/SCID). EPO has established imaging technologies to monitor in vivo tumor growth. | tumor model, pharmaceutical, oncology, in vitro, in vivo, antitumor, preclinical, pharmacology, pharmacokinetics, toxicology, anticancer, therapeutic, biomarker, imaging, testing, validation, target | is related to: OncoTrack | Tumor, Cancer | nlx_158355 | SCR_003954 | EPO - Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology Berlin-Buch, Experimental Pharmacology & Oncology Berlin-Buch GmbH, EPO Berlin-Buch GmbH, EPO-GmbH | 2026-02-14 02:00:53 | 2 | |||||||
|
Alacris Theranostics Resource Report Resource Website |
Alacris Theranostics (RRID:SCR_003953) | Alacris | commercial organization | Commercial organization that uses next generation sequencing technologies coupled with computational modeling of tumor and somatic tissues in order to identify individualized therapies for cancer patients. The company also uses these technologies to help pharmaceutical partners stratify patients for their clinical trials. Alacris has an exclusive worldwide commercial license for the computational modeling of tumors and somatic tissues using proprietary computational systems modeling technologies ModCell developed at the Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin coupled with next generation sequencing and genotyping technology developed at Harvard Medical School in Boston. The company also is building up the first next generation sequencing center in Europe for clinical operations. | next generation sequencing, computational modeling, clinical trial, somatic tissue, genotyping, genomics, oncogenomics, diagnostics, therapy, disease model, drug, personalized medicine, biomarker, drug development, tumor model, analysis, oncology | is related to: OncoTrack | Tumor, Cancer | nlx_158354, grid.473915.d | https://ror.org/04a0gnr15 | SCR_003953 | Alacris Theranostics GmbH | 2026-02-14 02:00:34 | 0 | ||||||
|
Hoosier Cancer Research Network Resource Report Resource Website |
Hoosier Cancer Research Network (RRID:SCR_004026) | HCRN | nonprofit organization | An independent nonprofit cancer research organization that provides full-service clinical trial management and support, from conception and study design through project completion and publication. Established to explore and develop leading edge cancer treatments across the United States and internationally, their clinical trials, developed in collaboration with academic and community oncologists, are conducted within a member network of more than 130 clinical research sites. Their vision and mission is to form unparalleled relationships between academic, community, pharmaceutical, and biotech partners with the goal of advancing cancer research, education, and patient advocacy. There are no costs to become a member. | oncology, clinical trial, clinical | is parent organization of: Big Ten Cancer Research Consortium | Cancer | nlx_158453, Wikidata: Q30287333, grid.428706.f | https://ror.org/02mtpb511 | SCR_004026 | Hoosier Oncology Group | 2026-02-14 02:00:55 | 0 | ||||||
|
BC Cancer Agency Resource Report Resource Website 1+ mentions |
BC Cancer Agency (RRID:SCR_004201) | BCCA | institution | A portal that provides a province-wide, population-based cancer control program for the residents of British Columbia and the Yukon. The BC Cancer Agency''s mandate covers the spectrum of cancer care, from prevention and screening, to diagnosis, treatment, and through to rehabilitation. The BC Cancer Agency''s mandate is driven by a three-fold mission: 1. To reduce the incidence of cancer; 2. To reduce the mortality rate of people with cancer; 3. To improve the quality of life of people living with cancer. This mission drives everything we do, including providing screening, diagnosis and care, setting treatment standards, and conducting research into causes of, and cures for, cancer. The BC Cancer Agency operates five regional cancer centers, providing assessment and diagnostic services, chemotherapy, radiation therapy, and supportive care. Each of the BC Cancer Agency''s centers delivers cancer treatment based on provincial standards and guidelines established by the Agency. We work in partnership with communities to provide a network of chemotherapy clinics so patients can receive care closer to home. Research is an essential part of the BC Cancer Agency''s mission to not only find the causes of cancer, but to find better treatments for prolonged life and better quality of life. With direct links between the BC Cancer Agency''s physicians and researchers at our five centers, the Deeley Research Centre (located in Victoria) and the BC Cancer Agency''s Research Centre (located in Vancouver), we can quickly translate new discoveries into clinical applications. The BC Cancer Agency''s Research Centre includes eight specialty laboratories including the Genome Sciences Centre, and the Terry Fox Laboratory. The BC Cancer Foundation raises funds for cancer research and enhancements to care at the BC Cancer Agency. |
is related to: BC Cancer Foundation is parent organization of: cisRED: cis-regulatory element is parent organization of: British Columbia Gynaecologic Tissue Bank is parent organization of: British Columbia Tumour Tissue Repository is parent organization of: Spark is parent organization of: ALEA is parent organization of: APOLLOH is parent organization of: British Columbia Breast Cancer Tumour Bank is parent organization of: JointSNVMix is parent organization of: mutationSeq is parent organization of: Mouse Gene Expression at the BC Cancer Agency is parent organization of: C. elegans Resources is parent organization of: BCCA Cancer Drug Manual is parent organization of: flowCL is parent organization of: flowBin |
Cancer | BC Cancer Foundation | ISNI: 0000 0001 0702 3000, Wikidata: Q4835275, grid.248762.d, nlx_143635, Crossref funder ID: 501100005614 | https://ror.org/03sfybe47 | SCR_004201 | British Columbia Cancer Agency | 2026-02-14 02:00:57 | 3 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the ASWG Resources search. From here you can search through a compilation of resources used by ASWG and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that ASWG has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on ASWG then you can log in from here to get additional features in ASWG such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into ASWG you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Welcome to the ASWG Community.
Our Information
